According to the consensus proposal for HCV genotype nomenclature published in 2005 (
4), for provisional subtype assignment two criteria should be met: (
1) at least three examples of infection with the new subtype should be described, otherwise the subtype remains unassigned; (
2) sequences of both the core/E1 and the NS5B regions are required. The core/E1 sequence should correspond to at least 90% of nucleotides of positions 869 - 1292 in the H77 reference sequence (AF009606). The NS5B sequence should correspond to at least 90% of nucleotides of positions 8276 – 8615 in the H77 reference sequence.
In 2006, Amini et al. reported two Iranian HCV isolates that belonged to a new subtype of genotype 3 (
15). According to their report, for both isolates, core regions (DQ202323 and DQ065830) were analyzed. For the second isolate, 5’UTR (DQ202322) and NS5B (DQ202324) regions were also analyzed. Regarding the analyzed segments of the genome, these two isolates were genetically more close to subtypes 3h and 3k in comparison with other subtypes of genotype 3. The genetic distances of the new isolates from subtypes 3h and 3k, however, were further from where they could be classified as any of these two subtypes. Eventually, this report suggested that the new isolates could be provisionally assigned as subtype 3l, although the positions of the reported sequences did not correspond to the positions that are required to be analyzed prior to subtype assignment.
Since 2006, no other report has been published about this new subtype. This might be mainly due to the fact that in the only published study (
15), reported sequences were from parts of the HCV genome that did not correspond to the core/E1 and the NS5B regions usually used for HCV genotyping. Consequently, although some other sequences were deposited in the HCV database, the relatedness of these sequences to the new subtype remained undiscovered.
In this study, we sequenced different parts of the genome of an Iranian HCV isolate (FSM165), which seemed to belong to a new subtype of genotype 3. We assessed the relatedness of this isolate to the new subtype reported in 2006 and found that isolate FSM165 was related to the new HCV subtype. Furthermore, we found other sequences in the HCV database and demonstrated that they also belonged to this new subtype.
According to our results, the discussed isolates should be classified as a new subtype of HCV genotype 3. Considering the 2005 consensus proposal (
4), however, these isolates do not have the criterion of availability of both the core/E1 and the NS5B sequences obtained from at least three unrelated infected individuals. It seems that there is a lack of complete agreement on assigning a name to this new subtype. In the Los Alamos HCV database, the new subtype has been provisionally assigned as 3l whereas in the European HCV database no such subtype has been considered among provisional subtypes of genotype 3. Very recently, complete genomic sequence of a new but yet-unassigned subtype of genotype 3 was reported from Canada (
14). Assigning a subtype to the new Canadian isolate in the near future would clarify the issue of whether the new Iranian subtype could be provisionally assigned as subtype 3l or it should be assigned with the next available letter once all of the sequences required by the 2005 consensus proposal are available. Needless to say, full-genome sequence characterization would be of utmost significance and lead to confirmation of this new subtype.
Currently, epidemiological data on the new HCV-3 subtype is lacking. The new subtype has been isolated from infected individuals residing in three provinces of Iran: Tehran (Central North), Lorestan (Central West) and Khouzestan (South West). Considering these regions, it seems that the new subtype has a vast geographical distribution in Iran. However, isolation of this subtype from other countries has not been reported so far. Thus, it seems that this HCV-3 subtype is endemic in Iran. The frequency of this subtype among Iranian HCV-infected individuals is unknown. According to the results of this study, only 5 isolates with the new subtype have been identified so far. This is not necessarily indicative of the low prevalence of the new subtype among Iranian patients because there are only a few studies, that used a phylogenetic approach to investigate HCV epidemiology in Iran. Therefore, more phylogenetic studies are necessary to determine the frequency of this new subtype.
In conclusion, phylogenetic analyses revealed the relatedness of an HCV isolate obtained from an Iranian patient in this study together with several HCV nucleotide sequences from the data base to a new subtype of genotype 3. It seems that the new subtype is endemic in Iran and it has been circulating among Iranian HCV-infected individuals for several years. Moreover, evidence shows that the new subtype has a vast geographical distribution in Iran. The core/E1 and the NS5B sequences described in this paper can be used as references for the new HCV subtype in future studies and pave the way for provisional assignment of this new subtype.